TABLE II.
Univariate analysis of the immunohistologic features of basal-like breast cancer and BRCA1/2 mutations
| Feature and status | Overall (n) | BRCA1 | BRCA2 | Non-BRCA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
||||||||
| (n) | (%) | p Value | (n) | (%) | p Value | (n) | (%) | |||
| CK5/6 | Negative | 143 | 6 | 4.2 | 0.002 | 11 | 7.7 | 0.299 | 126 | 88.1 |
| Positive | 46 | 9 | 19.6 | 1 | 2.2 | 36 | 78.2 | |||
| EGFR | Negative | 199 | 10 | 5.0 | 0.020 | 17 | 8.5 | 0.082 | 172 | 86.5 |
| Positive | 60 | 9 | 15.0 | 1 | 1.7 | 50 | 83.3 | |||
| p53 | Negative | 292 | 15 | 5.1 | 0.209 | 22 | 7.5 | 0.054 | 255 | 87.4 |
| Positive | 119 | 10 | 8.4 | 3 | 2.5 | 106 | 89.1 | |||
| ER | Negative | 136 | 20 | 14.7 | <0.001 | 6 | 4.4 | 0.385 | 110 | 80.9 |
| Positive | 275 | 5 | 1.8 | 19 | 6.9 | 251 | 91.3 | |||
| PR | Negative | 173 | 20 | 11.6 | <0.001 | 10 | 5.8 | 0.827 | 143 | 82.6 |
| Positive | 238 | 5 | 2.1 | 15 | 6.3 | 218 | 91.6 | |||
| HER2 | Negative | 311 | 23 | 7.4 | 0.056 | 24 | 7.7 | 0.017 | 264 | 84.9 |
| Positive | 97 | 2 | 2.1 | 1 | 1.0 | 94 | 96.9 | |||
| TNBC | Negative | 318 | 6 | 1.9 | <0.001 | 19 | 6.0 | 0.866 | 293 | 92.1 |
| Positive | 93 | 19 | 20.4 | 6 | 6.5 | 68 | 73.1 | |||
CK5/6 = cytokeratin 5/6; EGFR = epidermal growth factor receptor; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; TNBC = triple-negative breast cancer.